Mural Oncology PLC Logo

Mural Oncology PLC

Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.

Overview

Corporate Details

ISIN(s):
IE000LK2BOB4
LEI:
Country:
N/A
Address:
N/A
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Mural Oncology PLC is a clinical-stage oncology company focused on developing novel immunotherapies to treat cancer. The company leverages its proprietary protein engineering platform and expertise in cytokine biology to design and advance a pipeline of cytokine-based therapies. Its mission is to unlock the value of immunotherapy for a broader range of patients, particularly those with cancers that have not responded to previous treatments. The company's lead candidate, nemvaleukin alfa, is a novel, engineered interleukin-2 (IL-2) variant immunotherapy currently in clinical trials for difficult-to-treat solid tumors, including advanced melanoma and platinum-resistant ovarian cancer.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Mural Oncology PLC and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Mural Oncology PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Mural Oncology PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM

Talk to a Data Expert

Have a question? We'll get back to you promptly.